iShares MSCI Malaysia ETF vs Heron Therapeutics Inc — how do they compare? iShares MSCI Malaysia ETF trades at $28.07, while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: iShares MSCI Malaysia ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| EWM | HRTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $30.42 | $1.49 |
52-Week Low | $24.73 | $0.32 |
Market Cap | — | $63.41M |
Enterprise Value | — | $161.31M |
Signals from Pluang's Aura AI — not financial advice
EWM (iShares MSCI Malaysia ETF) trades at $28.18, up 0.28% with a bullish technical signal from moving averages. The ETF offers concentrated exposure to Malaysia's financial (54%) and industrial (21%) sectors, benefiting from data center expansion and tourism initiatives. Key support and resistance cluster around $28, with neutral oscillators suggesting balanced momentum.
Outlook remains positive due to Malaysia's structural growth drivers, though financial ratios are unavailable. Risks include energy supply constraints and regional currency volatility. Institutional sentiment leans bullish with 11 buy signals, but investors should monitor Malaysia's economic policies and global macro conditions.
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Trailing returns across standard periods
Latest headlines on both assets
EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →